A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease
Iris Dotan(Tel Aviv University), D. Hommes(Leiden University Medical Center), C. Maaser(University of Münster), Daniel Rachmilewitz(Hadassah Academic College), Alan L. Buchman(Northwestern University), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Douglas Edward Homoky(Ballad Health), B. Bokemeyer, Asher Kornbluth(Icahn School of Medicine at Mount Sinai), R Eliakim(Rambam Health Care Campus), C. Janneke van der Woude(Radboud University Nijmegen), Uma Mahadevan(University of California, San Francisco), T Plasse(Cytokinetics (United States)), B. E. Powers(Cytokinetics (United States)), P. Rutgeerts(Universitair Ziekenhuis Leuven), Eran Goldin(Hadassah Academic College), Ursula Seidler(Medizinische Hochschule Hannover)
Cited by 56
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k